PP04   Presentation Time: 10:27 AM
Brachytherapy (BT) boost with vaginal packing (VP) is standard of care for locally advanced cervical cancer. The goals of VP are to physically displace bladder and rectum (OARs) from the high dose radiation region and to stabilize the BT applicators. The BrachyGel Vaginal Hydrogel Packing System (BrachyGel) was developed as a new technique to improve the quality of VP for cervical cancer BT, including OAR dosimetry, patient comfort, ease of physician use, reproducibility, and visibility on MRI. The purpose of this study was to determine how the use of BrachyGel compares to standard gauze during high dose rate (HDR) BT for ...
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Kara Romano, Kristin Ward, Michael D. Schad, Wendy Zheng, Matthew Mistro, Bruce P. Libby, Christopher McLaughlin, Timothy N. Showalter, Gina Petroni, Einsley M. Janowski Source Type: research

PP05   Presentation Time: 10:36 AM
This study sought to evaluate potential of nine direction modulated brachytherapy (DMBT) tandem applicator models of unique designs to effectively removing the need for IS needles in a range of IC-IS cases found in multi-institutional clinics via achieving equivalent or better dosimetry. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Binod Manandhar, Somayeh Gholami, Dylan Richeson, Sharmin Alam, Suman Gautam, Daniel Scanderbeg, Catheryn M. Yashar, Joann Prisciandaro, Shruti Jolly, Emma Fields, William Y. Song Source Type: research

PP06   Presentation Time: 10:45 AM
In this study we aim to introduce a novel tandem applicator design in alignment with the direction modulated brachytherapy (DMBT) concept, called “honeycomb”, to address this important issue. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Moeen Meftahi, William Y. Song Source Type: research

Friday, June 23, 20231:30 PM - 2:45 PMPL01 Presentation Time: 1:30 PM
To evaluate efficacy results of the GEC-ESTRO phase III non-inferiority trial in subgroups of patients defined by the ASTRO criteria for patient selection for APBI. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Vratislav Strnad, Csaba Polg ár, Oliver Ott, Guido Hildebrandt, Daniela Kauer-Dorner, Hellen Knauerhase, Tibor Major, Jaroslaw Lyczek, Jose Luis Guinot, Cristina Gutierrez Miguelez, Pavel Slampa, Kristina Lössl, Bülent Polat, Niehoff Peter, Christine G Tags: Plenary Session Source Type: research

PL02   Presentation Time: 1:45 PM
High dose-rate brachytherapy is increasingly being used as monotherapy for low and intermediate risk prostate cancer. A dose of 27 Gy in 2 fractions is endorsed by the NCCN Guidelines, although with limited data on long-term efficacy. Our objective is to determine long-term efficacy of HDR monotherapy delivered as either a single fraction of 19 Gy or as two fractions of 13.5 Gy from a prospective randomized trial. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Gerard Morton, Hans Chung, Merrylee McGuffin, Eric Tseng, Andrea Deabreu, Liying Zhang, Jiheon Song, Matthew Wronski, Melanie Davidson, Moti Paudel, Andrew Loblaw Source Type: research

PL03   Presentation Time: 2:00 PM
Pre-planning of needle trajectories for the design of patient-specific 3D printed templates for interstitial gynaecological (GYN) high dose rate (HDR) brachytherapy (BT) is currently a time-consuming manual process, taking even experienced planners between 1-6 hours. A novel automated planning algorithm, which generates candidate needle trajectory sets for patient-specific cylinder templates (PSCTs) in approximately 10 minutes, is presented. Treatment plans generated using autoplanned needle trajectories are evaluated in a retrospective patient cohort. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Michael Kudla, Deidre Batchelar, Tony Teke Source Type: research

PL04   Presentation Time: 2:15 PM
Organ preservation for patients diagnosed with rectal cancer is an increasingly popular treatment strategy. In this paradigm, prospective data and early results from randomized trials suggest improved success rates with endoluminal radiotherapy techniques over external beam radiotherapy counterparts. We have previously published the interim analysis of the randomized phase II-III Morpheus trial, exploring the efficacy of external beam radiotherapy boost (EBRT, Arm A) against adaptive brachytherapy boost (BT, Arm B). (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Aurelie Garant, Marylise Boutros, Talia Malagon, Emma Starr, Te Vuong Source Type: research

Friday, June 23, 20234:45 PM - 5:45 PMMSOR1 Presentation Time: 4:45 PM
The U.S. healthcare system is a major generator of greenhouse gas (GHG) emissions, with operating rooms contributing an estimated 30% of hospital waste. Biohazardous (i.e., red bag) waste is a significant contributor to this waste stream and is known to have a significant environmental impact and financial cost, with disposal of red bag waste costing 11x more than landfill. Traditional brachytherapy waste audit protocols have been designed to track red bag waste, but they can be time-and resource-intensive. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Katie Lichter, Christina Phuong, John Liu, Lisa Ni, Alexis Smith, Jin Shin, Steve Braunstein, I-Chow Hsu, Nicolas Prionas, Osama Mohamad Tags: Scientifc Session: Miscellaneous Snap Orals I Source Type: research

MSOR2   Presentation Time: 4:50 PM
The Jefferson/Wills Eye plaque program is a robust weekly patient load of 5-7 plaque insertions. For the required custom-built construction of these plaques on a weekly basis, the Iodine (I-125) seeds of different source strengths are recycled. Seeds are returned to the correct batch without the need to assay individual seeds, a process that is quite time consuming, we have developed a novel 3D-printed conical QA holder for batch relative assay. This device permits reproducible placement of the constructed eye plaque for relative apparent activity measurements using a calibrated well-chamber. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Jacqueline Emrich, Firas Mourtada Source Type: research

MSOR3   Presentation Time: 4:55 PM
For high-dose-rate (HDR) brachytherapy treatments, where large doses are delivered in each fraction of treatment, it is critical to ensure that treatments are delivered according to the written directive because even small deviations in the treatment can lead to excessive dose to unwanted areas or critical structures. Against our best efforts, these deviations do occur and every fiscal year, the Nuclear Regulatory Commission (NRC) is required to compile a report listing all Abnormal Occurrences (AOs) to the U.S. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Elizabeth Jaye, Tarun Podder Source Type: research

MSOR4   Presentation Time: 5:00 PM
Treatment strategy of hepatocellular carcinoma (HCC) and Vp4 [main trunk] portal vein tumor thrombosis (PVTT) remains limited due to post treatment liver failure. We aimed to assess the efficacy of irradiation stent placement with 125I plus transcatheter arterial chemoembolization (TACE) (ISP-TACE) compared to sorafenib plus TACE (Sora-TACE) in these patients. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Jian Lu, Jin-He Guo, Gao-Jun Teng Source Type: research

MSOR5   Presentation Time: 5:05 PM
Suture placement by the ocular oncology surgeon is a necessary critical step prior to insertion of a radioactive plaque for ocular melanoma brachytherapy. This step relies on placement of a “dummy” plaque with the exact dimensions of the radioactive plaque. The purpose of this project is to create a custom dummy plaque applicator for the 22 mm notched gold plaque using in-house 3D printing. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Firas Mourtada, Sara Belko, Robert Pugliese, Lydia Komarnicky-Kocher, Carol Shields, Jacqueline Emrich Source Type: research

MSOR6   Presentation Time: 5:10 PM
Esophageal Brachytherapy has been an option for recurrent or persistent esophageal cancer after standard chemoradiation therapy. RTOG 9207 utilized esophageal brachytherapy as a boost technique with 15 Gy in 3 fractions after chemotherapy and radiation. Preliminary analysis showed 17% fistula formation and since then the technique has been underutilized. We reviewed all patients that were treated at our institution in the last 5 years to assess disease outcomes including overall survival, local control and toxicity. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Nitika Thawani, Allison Morrow, Shyamal Patel, Ross Bremner, Mital Patel, Shiv Srivastava, Dilini Pinnaduwage, Vamsee Torri, Savio Reddymasu, Subhakar Mutyala Source Type: research

MSOR7   Presentation Time: 5:15 PM
To evaluate the oncological results in local control and vision preservation at 5 years with ocular brachytherapy treatment with I-125 in the largest cohort of patients in Colombia and one of the largest in Latin America, given that the National Institute of Canerology Bogota-Colombia has an important recognition in being the only institution that performs this management in the country. In an emerging country with limited resources, where surgical management with exenteration for some neoplasms such as uveal melanomas is the treatment standard, ocular brachytherapy is becoming increasingly important. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Javier Rodriguez Corredor Source Type: research

MSOR8   Presentation Time: 5:20 PM
Delays in initiating and completing brachytherapy may have adverse oncologic outcomes for patients with cervical, uterine, and prostate cancer. During the Coronavirus disease-19 (COVID-19) pandemic, the United States healthcare system experienced an unprecedented impact on medical resources, personnel, and patient access to routine care. The impact of the COVID-19 pandemic on brachytherapy in the United States has not been well-characterized. We aim to evaluate how a diagnosis of COVID-19 affected the timeliness of treatment for patients undergoing brachytherapy for cervical, uterine, and prostate cancer nationally. (Source: Brachytherapy)
Source: Brachytherapy - September 1, 2023 Category: Cancer & Oncology Authors: Eric Roach, Ryan Hutten, Skyler Johnson, Gita Suneja, Jonathan Tward, Daniel Petereit, David Gaffney Source Type: research